{"id":10266,"date":"2025-10-19T15:13:42","date_gmt":"2025-10-19T13:13:42","guid":{"rendered":"http:\/\/pepticore-aminos.local\/?post_type=product&p=10266"},"modified":"2026-05-29T17:25:20","modified_gmt":"2026-05-29T15:25:20","slug":"tirzepatide-10mg","status":"publish","type":"product","link":"https:\/\/pepticoreaminos.us\/en\/product\/tirzepatide-10mg\/","title":{"rendered":"Tirzepatide 10mg"},"content":{"rendered":"
\n
\n

Tirzepatide<\/h1>\n

Dual GIP\/GLP-1 peptide for research on diabetes, obesity, and metabolism.<\/p>\n<\/header>\n

\n

What is Tirzepatide<\/h2>\n

Tirzepatide<\/strong> is a next-generation peptide molecule developed for the treatment of type 2 diabetes<\/strong> and obesity<\/strong>.\nIt is the active compound in the commercial drug Mounjaro<\/strong>, approved worldwide as a dual agonist of the GIP<\/strong> (glucose-dependent insulinotropic polypeptide) and GLP-1<\/strong> (glucagon-like peptide-1) receptors.\nThis combination of hormonal targets allows simultaneous action on blood glucose regulation, lipid metabolism, and appetite control.<\/p>\n

Unlike previous GLP-1 agonists, Tirzepatide produces a synergistic effect<\/strong> that improves glycemic control<\/strong>, promotes significant and long-lasting weight loss<\/strong>, and enhances the body\u2019s overall energy efficiency.\nIn subjects with obesity, treatment with Tirzepatide has shown body weight reductions of up to 22.5%<\/strong> over 72 weeks, as reported in the reference study SURMOUNT-1 (NEJM 2022)<\/a>.<\/p>\n<\/article>\n

\n

Mechanism of Action: synergy between GIP and GLP-1<\/h2>\n

Tirzepatide<\/strong> mimics the combined action of two natural intestinal hormones, GIP<\/strong> and GLP-1<\/strong>, known as incretins.\nThese hormones are secreted after meals and contribute to the regulation of glucose and fat metabolism.\nBy acting on both receptors, Tirzepatide amplifies the signals that control insulin secretion<\/strong>, reduces glucagon levels<\/strong>, and modulates the brain centers of appetite<\/strong>.<\/p>\n

GIP Receptor<\/h3>\n

The GIP receptor<\/strong> stimulates the pancreas to release insulin only when blood glucose levels are high, minimizing the risk of hypoglycemia.\nIt also participates in fat metabolism by influencing the use of fatty acids as an energy source.\nIn combination with GLP-1, this pathway promotes the reduction of visceral fat<\/strong>, the type most closely associated with cardiovascular risk and insulin resistance.<\/p>\n

GLP-1 Receptor<\/h3>\n

Activation of the GLP-1 receptor<\/strong> reduces hunger, slows gastric emptying, and stimulates insulin secretion in response to glucose.\nAt the same time, it inhibits the release of glucagon, thereby lowering blood sugar levels.\nThe combined effect improves HbA1c<\/strong>, stabilizes fasting glucose, and facilitates the maintenance of a prolonged caloric deficit.<\/p>\n

This dual endocrine action underlies the success of Tirzepatide, combining the antidiabetic properties<\/strong> of GLP-1 with a broader metabolic impact mediated by GIP.\nClinical results also suggest a potential role in improving vascular health<\/strong>, reducing blood pressure<\/strong>, and lowering systemic inflammatory markers<\/strong><\/p>\n<\/article>\n

\n

Main Observed Benefits<\/h2>\n